71 related articles for article (PubMed ID: 11309362)
1. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity.
Narla RK; Dong Y; Klis D; Uckun FM
Clin Cancer Res; 2001 Apr; 7(4):1094-101. PubMed ID: 11309362
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
3. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent.
Narla RK; Dong Y; D'Cruz OJ; Navara C; Uckun FM
Clin Cancer Res; 2000 Apr; 6(4):1546-56. PubMed ID: 10778988
[TBL] [Abstract][Full Text] [Related]
4. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity.
D'Cruz OJ; Uckun FM
Expert Opin Investig Drugs; 2002 Dec; 11(12):1829-36. PubMed ID: 12457442
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells.
Liu J; Lu H; Huang R; Lin D; Wu X; Lin Q; Wu X; Zheng J; Pan X; Peng J; Song Y; Zhang M; Hou M; Chen F
Cancer Chemother Pharmacol; 2005 Oct; 56(4):400-8. PubMed ID: 15838654
[TBL] [Abstract][Full Text] [Related]
6. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
7. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes.
Parmo-Cabañas M; Molina-Ortiz I; Matías-Román S; García-Bernal D; Carvajal-Vergara X; Valle I; Pandiella A; Arroyo AG; Teixidó J
J Pathol; 2006 Jan; 208(1):108-18. PubMed ID: 16278822
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes.
Dong Y; Narla RK; Sudbeck E; Uckun FM
J Inorg Biochem; 2000 Mar; 78(4):321-30. PubMed ID: 10857913
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
10. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
11. The calpastatin-derived calpain inhibitor CP1B reduces mRNA expression of matrix metalloproteinase-2 and -9 and invasion by leukemic THP-1 cells.
Popp O; Heidinger M; Ruiz-Heinrich L; Ries C; Jochum M; Gil-Parrado S
Biol Chem; 2003 Jun; 384(6):951-8. PubMed ID: 12887063
[TBL] [Abstract][Full Text] [Related]
12. Novel copper(II) complex of N-propyl-norfloxacin and 1,10-phenanthroline with enhanced antileukemic and DNA nuclease activities.
Katsarou ME; Efthimiadou EK; Psomas G; Karaliota A; Vourloumis D
J Med Chem; 2008 Feb; 51(3):470-8. PubMed ID: 18205294
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
Narla RK; Liu XP; Klis D; Uckun FM
Clin Cancer Res; 1998 Oct; 4(10):2463-71. PubMed ID: 9796979
[TBL] [Abstract][Full Text] [Related]
14. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis inducing novel anti-leukemic agent, bis(4,7-dimethyl-1,10 phenanthroline) sulfatooxovanadium(IV) [VO(SO4)(Me2-Phen)2] depolarizes mitochondrial membranes.
Narla RK; Dong Y; Uckun FM
Leuk Lymphoma; 2001 May; 41(5-6):625-34. PubMed ID: 11378580
[TBL] [Abstract][Full Text] [Related]
16. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
17. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
18. Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells.
Kim SY; Kim DH; Han SJ; Hyun JW; Kim HS
Biochem Pharmacol; 2007 Dec; 74(11):1642-51. PubMed ID: 17880928
[TBL] [Abstract][Full Text] [Related]
19. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases.
Chen SH; Gillespie GY; Benveniste EN
Glia; 2006 Jan; 53(2):191-200. PubMed ID: 16206166
[TBL] [Abstract][Full Text] [Related]
20. Heterocyclic organobismuth(III) induces apoptosis of human promyelocytic leukemic cells through activation of caspases and mitochondrial perturbation.
Iuchi K; Hatano Y; Yagura T
Biochem Pharmacol; 2008 Oct; 76(8):974-86. PubMed ID: 18760261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
